Seismic Therapeutic Congratulates Dr. Timothy A. Springer, Winner of the 2022 Lasker Award

CAMBRIDGE, Mass., September 28, 2022 – Seismic Therapeutic, Inc., today congratulated Timothy A. Springer, PhD, for his selection as a co‑recipient of the 2022 Albert Lasker Basic Medical Research Award, one of the most prestigious awards in medicine. Dr. Springer is a founding investor and academic co-founder of Seismic Therapeutic.

Dr. Springer (Boston Children’s Hospital/Harvard Medical School) is a co-winner of this year’s Lasker Award along with Richard O. Hynes, PhD, (Massachusetts Institute of Technology) and Erkki Ruoslahti, MD, PhD, (Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA) for discoveries in their respective labs concerning a family of transmembrane proteins called integrins. In a statement, the Lasker Foundation cited the work of Drs. Springer, Hynes and Ruoslahti “for discoveries concerning the integrins—key mediators of cell-matrix and cell-cell adhesion in physiology and disease.”

Dr. Springer is the Latham Family Professor and Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, and Principal Investigator and Professor of Medicine, Program in Cellular and Molecular Medicine, Boston Children’s Hospital. His discoveries have led to novel therapeutic strategies to treat a variety of autoimmune disorders, which is the disease area for Seismic’s drug development that integrates machine learning.

About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to treat adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit

Media Contact
Kathryn Morris, The Yates Network



This links to an external website.